Type 2 diabetes patients on GLP-1 treatments, including Ozempic, have a lower risk of 10 types of obesity-related cancers compared to those on insulin, according to a new study.
Patients with type 2 diabetes taking GLP-1 treatments, which include Ozempic, have a lower chance of developing 10 types of obesity-related cancers than those taking insulin and other diabetes drugs, according to a study published on Friday. GLP-1 treatments for type 2 diabetes have been on the market for nearly 20 years. The newer generation - such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro - are far more effective at controlling blood sugar levels and inducing weight loss.
The study did not specify which GLP-1 medicines the patients took, but the records were for patients on these medicines or insulin or the diabetes drug metformin between March 2005 and November 2018. Ozempic was only approved by the U.S. Food and Drug Administration in December 2017. The study found that the patients treated with a GLP-1 therapy instead of insulin 'had a significant risk reduction' in 10 of those cancers.
The versions of these medicines that are approved to treat obesity, and have been shown to help patients lose as much as 20% of their weight on average, have exploded in popularity, leading to record profits for Novo and Lilly. Lilly's Mounjaro and weight-loss therapy Zepbound, as well as Novo's rival medicines Ozempic and Wegovy are already being studied to see whether they can improve health in many other ways, ranging from alcohol addiction to sleep apnea. In March, the U.S.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Type 2 Diabetes Drug Class Could Benefit Teens With Type 1The sodium-glucose cotransporter-2 inhibitor dapagliflozin improved A1c and kidney function with just 1 case of mild diabetic ketoacidosis, although blood ketones increased.
Read more »
Non-Diabetic Use Of GLP-1 Drugs Like Ozempic For Weight Loss Affecting Retail Sizing CurvesI've been a journalist for 30 years, as a senior editor at W magazine, and for the last 17 years, covering retail and real estate as a senior editor at WWD. I write about luxury boutiques, independent retailers, department stores, mass chains, and digitally native brands, and the force that's redefining the way we shop – Amazon.
Read more »
Ozempic and Other GLP-1 Drugs May Cut Cancer RiskNew research suggests GLP-1 drugs like Ozempic can help prevent up to 10 different obesity-related cancers in people with type 2 diabetes.
Read more »
Beyond Ozempic: New GLP-1 drugs promise weight loss and health benefitsThe World Health Organization issued an alert on falsified versions of Ozempic, the popular drug used to treat type 2 diabetes and obesity. The WHO warned health care professionals and the public to be aware of the counterfeits, which it said are increasing as demand for the drugs grows. NBC News' Anne Thompson reports.
Read more »
Forget Ozempic and Wegovy — Utahns embracing natural solution to boost GLP-1Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost GLP-1 levels in the body.
Read more »
Use of weight loss and diabetes drugs like Ozempic has skyrocketed in Mass.Research released by the state's Health Policy commission Thursday showed number of Massachusetts residents prescribed a relatively new class of weight management and diabetes drugs has increased sevenfold over five years. The medications include the brand name drugs Ozempic, Wegovy and Mounjaro.
Read more »